Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth

Status: Completed

Conditions: Escherichia Coli Infections; Klebsiella Infections; Gram-Positive Bacterial Infections

Treatments: Drug: piperacillin-tazobactam

Study type: Observational

Funder types: Industry

Identifiers

NCT00167999

0910X-101676

Details and patient eligibility

About

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eligible patients of either sex, 15 years of age or older
• Patients who are admitted to the department of hematology and oncology
• Provide written informed consent

Exclusion criteria

• Patients who have hypersensitivity to β-lactam antibiotics
• Female who are pregnant or breast-feeding
• Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days